Schuster Mikkel Bruhn, Porse Bo Torben
Section for Gene Therapy Research, Department of Clinical Biochemistry, Copenhagen University Hospital, Juliane Maries Vej 20-9322, DK2100 Copenhagen, Denmark.
Biochim Biophys Acta. 2006 Aug;1766(1):88-103. doi: 10.1016/j.bbcan.2006.02.003. Epub 2006 Mar 24.
The CCATT/enhancer binding protein alpha, C/EBPalpha, is a key transcription factor involved in late differentiation events of several cell types. Besides acting as a classical transcription factor, C/EBPalpha is also a well-characterized inhibitor of mitotic growth in most cell lines tested. In line with its anti-mitotic properties, C/EBPalpha has been shown to interact with, and alter the activities of, several cell cycle related proteins and a number of models as to the mechanistics of C/EBPalpha-mediated growth repression have been proposed. More recently, several reports have indicated that C/EBPalpha acts as a tumour suppressor in the hematopoietic system and that mutation within C/EBPalpha is sufficient to induce tumourigenesis. Here, we will review these data and probe the possibility that C/EBPalpha also act as a tumour suppressor in other C/EBPalpha-expressing tissues.
CCAAT/增强子结合蛋白α（C/EBPα）是一种关键转录因子，参与多种细胞类型的晚期分化事件。除了作为经典转录因子发挥作用外，在大多数测试的细胞系中，C/EBPα还是一种特性明确的有丝分裂生长抑制剂。与其抗有丝分裂特性一致，C/EBPα已被证明可与多种细胞周期相关蛋白相互作用并改变其活性，并且已经提出了一些关于C/EBPα介导的生长抑制机制的模型。最近，一些报告表明C/EBPα在造血系统中作为肿瘤抑制因子发挥作用，并且C/EBPα内的突变足以诱导肿瘤发生。在此，我们将综述这些数据，并探讨C/EBPα在其他表达C/EBPα的组织中也作为肿瘤抑制因子发挥作用的可能性。
